labetalol and dobutamine

labetalol has been researched along with dobutamine in 15 studies

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19901 (6.67)18.7374
1990's4 (26.67)18.2507
2000's3 (20.00)29.6817
2010's5 (33.33)24.3611
2020's2 (13.33)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Jones, LH; Nadanaciva, S; Rana, P; Will, Y1
Brockmöller, J; Dücker, C; Jensen, O1
Kashihara, M; Mizuguchi, M; Yokoyama, T1
Hicks, PR; Rankin, AP1
Bernard, R; Renard, M1
Downs, JB; Smith, RA; Thrush, D1
Hassan, E; Leslie, J; Martir-Herrero, ML1
Crooks, BN; Deshpande, SA; Hall, C; Milligan, DW; Platt, MP1

Reviews

1 review(s) available for labetalol and dobutamine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

14 other study(ies) available for labetalol and dobutamine

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
    Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21

    Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
    Bioorganic & medicinal chemistry letters, 2016, 08-15, Volume: 26, Issue:16

    Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone

2016
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
    Journal of medicinal chemistry, 2021, 03-11, Volume: 64, Issue:5

    Topics: Databases, Chemical; Drug Evaluation, Preclinical; HEK293 Cells; Humans; Machine Learning; Octamer Transcription Factor-1; Organic Chemicals

2021
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
    Journal of medicinal chemistry, 2021, 10-14, Volume: 64, Issue:19

    Topics: Amyloid Neuropathies, Familial; Anthelmintics; Bithionol; Crystallography, X-Ray; Drug Repositioning; Humans; Prealbumin; Thermodynamics; Triclabendazole

2021
Massive adrenaline doses in labetalol overdose.
    Anaesthesia and intensive care, 1991, Volume: 19, Issue:3

    Topics: Adult; Dobutamine; Dopamine; Drug Overdose; Epinephrine; Female; Humans; Isoproterenol; Labetalol

1991
[Heart failure and acute myocardial infarct. Current treatment].
    Bulletin et memoires de l'Academie royale de medecine de Belgique, 1983, Volume: 138, Issue:11

    Topics: Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Imidazoles; Labetalol; Myocardial Infarction; Phentolamine; Vasodilator Agents

1983
Continuous thermodilution cardiac output: agreement with Fick and bolus thermodilution methods.
    Journal of cardiothoracic and vascular anesthesia, 1995, Volume: 9, Issue:4

    Topics: Adrenergic Agonists; Adrenergic Antagonists; Animals; Bias; Carbon Dioxide; Cardiac Catheterization; Cardiac Output; Catheterization, Swan-Ganz; Computers; Confidence Intervals; Dobutamine; Glucose; Hemodynamics; Infusions, Intravenous; Labetalol; Oxygen; Oxygen Consumption; Prospective Studies; Reproducibility of Results; Spirometry; Swine; Thermodilution; Thermometers

1995
Stability of labetalol hydrochloride with selected critical care drugs during simulated Y-site injection.
    American journal of hospital pharmacy, 1994, Sep-01, Volume: 51, Issue:17

    Topics: Critical Care; Dobutamine; Drug Interactions; Drug Stability; Humans; Labetalol; Morphine; Nitroglycerin; Ranitidine

1994
Adverse neonatal effects of maternal labetalol treatment.
    Archives of disease in childhood. Fetal and neonatal edition, 1998, Volume: 79, Issue:2

    Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Cardiomegaly; Dobutamine; Dopamine; Drug Therapy, Combination; Fatal Outcome; Female; Glucagon; Humans; Infant, Newborn; Labetalol; Norepinephrine; Pericardial Effusion; Pregnancy; Pregnancy Complications, Cardiovascular; Prenatal Exposure Delayed Effects

1998